A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3337641 in Japanese and Caucasian Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Poseltinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Eli Lilly
- 25 Jun 2017 Status changed from active, no longer recruiting to completed.
- 21 Jun 2017 Planned End Date changed from 4 May 2017 to 1 Sep 2017.
- 21 Jun 2017 Status changed from recruiting to active, no longer recruiting.